The Clinical Impact of Low Doses of Dasatinib in Patients with Chronic Myeloid Leukemia
Makaleler > Tam Makale · 2012
Yazarlar: SALİH AKSU, Fahri ŞAHİN, Burak Uz, Selim A. Yavuz, Hilmi Atay, Engin Kelkitli, Mehmet Turgut, Mustafa Pehlivan, Meltem O. Akay, Emel Guray, Muzaffer Demir, Selda Kahraman, Fatih Demirkan, Semra PAYDAS, Giiray SAYDAM, Ibrahim C. Haznedaroglu
UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, SCI Expanded İndekslerine Giren Dergi, Uluslararası, 2012, cilt 22, ss 8-14
DOI: 10.4999/uhod.12004
Özet
We report our experience in 41 patients with chronic phase (CF)-chronic myeloid leukemia (CML) who had discontinued imatinib switched to dasatinib, retrospectively. The CF-CML patients received dasatinib at starting dose of 100 once daily. Dose adjustment were observed in 11 patients, respectively. In case of other circumstances, treatment has been continued with a lower dose if needed. The median dose of dasatinib was 100 mg daily (range: 50 to 140 mg). We conclude that even low-dose dasatinib therapy is an effective and safe in second line treatment of CML patients patients.